KMT2A and acute myeloid leukemia: Introducing the synergistic triplet combination of Menin inhibitors with HMA and venetoclax (HMA / VEN) into the first‐line treatment NPM1‐mutated or KMT2A‐rearranged AML patients unfit for intensive chemotherapy is the most obvious next step in the clinical development of these agents.